Arvinas, Inc. (ARVN)
NASDAQ: ARVN · IEX Real-Time Price · USD
24.85
-1.13 (-4.35%)
At close: Jul 2, 2024, 4:00 PM
24.50
-0.35 (-1.41%)
After-hours: Jul 2, 2024, 7:30 PM EDT
Arvinas Revenue
Arvinas had revenue of $71.30M in the twelve months ending March 31, 2024, down -48.07% year-over-year. Revenue in the quarter ending March 31, 2024 was $25.30M, a -22.15% decrease year-over-year. In the year 2023, Arvinas had annual revenue of $78.50M, a decrease of -40.26%.
Revenue (ttm)
$71.30M
Revenue Growth
-48.07%
P/S Ratio
23.85
Revenue / Employee
$160,225
Employees
445
Market Cap
1.70B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
Dec 31, 2016 | 6.67M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.62B |
National HealthCare | 1.17B |
Harmony Biosciences Holdings | 617.51M |
NeoGenomics | 610.66M |
Veracyte | 375.47M |
Zai Lab | 291.07M |
Immunocore Holdings | 264.25M |
Mirum Pharmaceuticals | 224.00M |
ARVN News
- 8 days ago - Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer - GlobeNewsWire
- 11 days ago - Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 - GlobeNewsWire
- 15 days ago - Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. - GlobeNewsWire
- 4 weeks ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress - GlobeNewsWire
- 6 weeks ago - Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) - GlobeNewsWire
- 7 weeks ago - Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress - GlobeNewsWire
- 2 months ago - Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire